100
Participants
Start Date
June 16, 2023
Primary Completion Date
March 4, 2025
Study Completion Date
March 28, 2025
Active Comparator CT1812
123 participants will receive a single daily dose of CT1812 (200 mg)
Placebo Comparator
123 participants will receive a single daily dose of placebo
Long Island Vitreoretinal Consultants, Great Neck
National Ophthalmic Research Institute, Fort Myers
Erie Retina Research, LLC, Erie
Retina Specialists, Baltimore
North Carolina Retina Associates, Wake Forest
Advanced Research, Deerfield Beach
Rand Eye Institute, Deerfield Beach
Center for Retina and Macular Disease, Winter Haven
Tennessee Retina, PC, Nashville
Star Vision Consultants, Burleson
Texas Retina Associates, Fort Worth
Retina Consultants of Texas, San Antonio
Austin Clinical Research, LLC, Austin
Phoenix Retina Associates, Phoenix
Bay Area Retina Associates, Walnut Creek
Retinal Consultants Medical Group, Sacramento
Verum Research LLC, Eugene
Ophthalmic Consultants of Boston, Boston
NJ Retina, Edison
Lead Sponsor
Cognition Therapeutics
INDUSTRY